Absci, a pioneer in AI-driven drug development, is partnering with Almirall, a leading global biopharmaceutical company in medical dermatology. Together, they aim to use artificial intelligence to design and bring to market innovative therapeutics for chronic dermatological diseases.
This collaboration expands Absci's de novo AI drug creation portfolio into dermatology, combining its Integrated Drug Creation™ platform with Almirall’s dermatological expertise. The goal is to advance the development of life-changing medicines, a significant step in AI-driven drug creation.
For Almirall, this marks its first de novo AI drug collaboration, following Absci's recent announcement of designing therapeutic antibodies using 'zero-shot' generative AI. Absci will utilise its de novo generative AI to create therapeutic candidates for two dermatological targets. The partnership includes royalties and potential payments of up to $650 million based on successful milestones.
Dr. Karl Ziegelbauer, Almirall's Executive VP of R&D and CSO, emphasised Absci's innovation in tackling challenging medical needs, stating, "Our partnership underlines Almirall’s commitment to target innovative approaches to help patients suffering from severe skin diseases to achieve their dream of leading a healthy life."
Sean McClain, Absci's Founder and CEO, highlighted the transformative potential, stating, "We believe the collaboration will generate insights for using AI drug creation to treat chronic inflammatory diseases more broadly, accelerating our journey in creating better biologics for diseases affecting millions daily."
Click here to read the original news story.